Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Alternative Names: BEAT-HIV programme; dMAb™

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; MedImmune; Wistar Institute
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Chikungunya virus infections; HIV infections; Influenza virus infections; Pneumonia; Prostate cancer

Most Recent Events

  • 08 Oct 2018 Preclinical development is ongoing in USA
  • 08 Oct 2018 Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals is available for licensing as of 08 Oct 2018. www.inovio.com
  • 08 Oct 2018 Pharmacodynamics data from a preclinical trial in Cancer released by Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top